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CONCLUSIONS: The FSS scale is an instrument reliable and valid to measure mus-
cular fatigue in Brazilian patients with myopathy.
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OBJECTIVES: To evaluate lung function decline before and after the initiation of
dornase alfa (DA) through a multivariable mixed-effects piecewise linear model
using data from the Epidemiologic Study of Cystic Fibrosis (ESCF). METHODS: Pa-
tients aged 8-38 years enrolled in ESCF for 2 or more years prior to initial treatment
with DA were selected if they remained on treatment for at least 2 years. A com-
parator group included cystic fibrosis patients not yet reported to have received DA.
FEV1 percent predicted (pp) was analyzed before and after an index measurement
within 30 days of either DA initiation (DA group) or an encounter within 1 year
following the 8th or subsequent even-numbered birthday (comparator group). For
each patient, we fit a regression line to FEV1 pp separately for the pre-index and
post-index periods (both 2 years in duration) using a mixed-effects piecewise linear
model adjusted for age, gender, pulmonary exacerbations, respiratory therapies,
and nutritional supplements. Patients were categorized by age group or by age-
adjusted deciles of the index FEV1 pp. RESULTS: The DA group (n2,230) had a
lower FEV1 pp at index and a more rapid decline during the pre-index period. There
was an acute improvement in FEV1 pp (change in intercept) associated with the
initiation of DA therapy. Furthermore, the mean rate of FEV1 pp decline was more
attenuated for the DA group than for the comparator group (n5,970) across age
groups and deciles. CONCLUSIONS: The use of DA for a 2-year period is associated
with both an acute improvement in FEV1 pp (previously shown in clinical trials)
and a reduction in the rate of FEV1 pp decline (shown for the first time). These
results demonstrate the value of using mixed-effects piecewise linear models in
observational studies to evaluate the effect of instituting a therapy on both the
slope and intercept of a continuous outcome.
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OBJECTIVES: The BURQOL-RD project is intended to develop a disease based model
capable of quantifying the socio-economic burden and Health-Related Quality of
Life (HRQOL) for patients with rare diseases (RD) and their caregivers in Europe. We
described the methodology used to select a set of 10 RD to be approached in a pilot
study. METHODS: BURQOL-RD project counts with 20 partners, from 8 European
countries: Spain, UK, France, Germany, Sweden, Italy, Hungary and Bulgaria. A
two-round Delphi process was used to generate consensus in the selection of the 10
RD among the project participants. The wide variability and dispersion of the re-
sponses received in the two Delphi rounds of prioritization suggested that an ad-
ditional procedure should be implemented to improve the representativeness of
selected diseases. A Lewis Carroll’s trilateral diagram was applied based on three
determinants. RESULTS: The two rounds of Delphi panel yielded into a prioritised
list, to which the Carroll diagram was applied, taking into account three determi-
nants: prevalence, availability of effective treatment and need for carer. The final
set of RD was obtained to be targeted in the pilot study of BURQOL-RD: Cystic
Fibrosis, Prader-Willi Syndrome, Haemophilia, Duchenne Muscular Dystrophy,
Epidermolysis Bullosa, Fragile X Syndrome, Sclerodermia, Mucopolysaccharidosis,
Juvenile Idiopathic Arthritis and Histiocytosis. CONCLUSIONS: This methodology
permitted to obtain an equilibrated set of RD for the pilot study of BURQOL-RD
project. The model that will be generated will not only be suitable to apply in a wide
range of RD but it will also be sufficiently flexible to identify and adapt to the
challenges faced by the different health and social care systems of EU member
states.
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BELATACEPT VERSUS TACROLIMUS: RESULTS OF AN INDIRECT ANALYSIS
FROM A SYSTEMATIC REVIEW OF IMMUNOSUPPRESSIVE THERAPIES FOR
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OBJECTIVES: To systematically identify and summarise the evidence of renal
transplant outcomes, toxicity and adverse effects in order to determine the most
effective options. In particular, comparing tacrolimus, the cornerstone of renal
transplantation therapy, with newer therapies that have been introduced since
2003.METHODS:An electronic literature search of MEDLINE, Current Contents and
the Cochrane Library databases was conducted, plus manual reference checks of
all articles involving controlled trials of kidney transplants and immunosuppres-
sive therapy between 2003 and July 2010. Studies were assessed for eligibility and
quality by two reviewers who extracted data independently. Studies were classified
according to CNI avoidance or reduction, steroid avoidance, and induction thera-
pies. Results were expressed as risk ratio (RR) with 95% confidence intervals (CI).
Where necessary, indirect comparison techniques were used to compare different
forms of tacrolimus with belatacept. RESULTS: Thirty-five studies from an initial
list of 2895 citations were included in the analysis. Results show CNI avoidance
leads to higher incidence of acute rejection (RR 2.52, 95% CI 1.11–5.75), which is a
known predictor for graft loss, but reduced chronic allograft nephropathy. Tacroli-
mus produces better rejection prophylaxis compared with ciclosporin (RR 0.38, 95%
CI 0.21–0.70), and ciclosporin produces lower acute rejection compared with be-
latacept (RR 0.32, 95% CI 0.19–0.55). Indirect analysis shows that tacrolimus is
superior to belatacept in acute rejection prophylaxis (RR 0.18, 95% CI 0.08–0.39), but
leads to more cases of a decrease in glomerular filtration rate (GFR) (RR 1.37, 95% CI
0.92–2.03); however, the long-term impact of a reduction in GFR in the context of a
CNI-free regimen is not clear at present. CONCLUSIONS: Direct and indirect com-
parisons demonstrate that CNIs, and in particular tacrolimus, remain superior
even against more recent compounds for preventing acute rejection. However,
more research needs to be done to find the optimum combination of therapies.
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OBJECTIVES: To evaluate the comparative effectiveness of investigational com-
pound ferumoxytol for the treatment of iron deficiency anaemia (IDA) associated
with chronic kidney disease (CKD) compared to alternative iron replacement ther-
apies (IRT). Primary interest was the improvement in haemoglobin (Hb) from base-
line levels.METHODS:A comprehensive systematic review was conducted to iden-
tify any randomised controlled trials investigating the efficacy of IRTs for the
treatment of IDA in CKD where efficacy is defined as Hb change from baseline and
IRTs included intravenous (IV) and oral treatments. Twelve electronic databases
were searched up to November 2010 (language unrestricted). Two reviewers inde-
pendently assessed each identified reference and conducted subsequent data ex-
traction. Method quality of each included trial was also independently assessed in
accordance with NICE guidelines. A standard meta-analysis comparing oral iron to
ferumoxytol was initially conducted, reflecting the trial programme. The full net-
work of evidence that included IV and oral iron therapies was synthesised using a
mixed treatment comparison (MTC). The random effects model showed ‘predicting
superiority’ to the fixed effects model and was thus utilised. Mean efficacy was
estimated through analysing standardised effect sizes of trials and back-trans-
forming data to Hb values via weighted average standard deviation. RESULTS:
Seventeen published trials and one unpublished clinical study provided the heter-
ogeneous trial base for MTC analysis. Ferumoxytol was significantly favoured
when compared to oral iron therapy by conventional meta-analysis (0.61; 95%
CI0.44,0.79; P value0.0001) which was supported by results from the MTC ef-
ficacy analysis (0.48; 95% CI1.24,2.2). Significant differences in efficacy were not
observed between ferumoxytol and any of the alternative IV iron therapies.
CONCLUSIONS: The results from the conventional meta-analysis showed that the
model favoured investigational compound ferumoxytol, in terms of increasing Hb,
in comparison to oral iron therapy and suggested a modelled equivalence to cur-
rently approved alternative IV iron treatments.
PUK3
SOURCES OF HETEROGENEITY AMONG OVERACTIVE BLADDER CLINICAL TRIAL
ESTIMATES OF TOLTERODINE AND FESOTERODINE REDUCTIONS OF URGENCY
URINARY INCONTINENCE EPISODES RELATIVE TO PLACEBO
Snedecor SJ
Pharmerit North America, LLC, Bethesda, MD, USA
OBJECTIVES: Explore potential sources of heterogeneity among estimates of tolt-
erodine (TOL) and fesoterodine (FESO) efficacy relative to placebo (PBO) in patients
with overactive bladder and urgency urinary incontinence (UUI) from randomized
clinical trials (RCTs) published from 2001 – 2010. METHODS: RCTs evaluating TOL
4mg, solifenacin 5mg and/or 10mg, or FESO 4mg or 8mg compared to PBO reporting
mean reduction of UUI episodes/d from baseline to endpoint were identified. Treat-
ment effects (treatment response minus PBO response) and PBO responses were
tested for heterogeneity using Cochran’s Q statistic. Where heterogeneity was
present, other study variables (baseline UUI, baseline micturitions, gender, age,
diary evaluation days, publication year, and study duration) were evaluated for
potential confounding using linear regression methods. RESULTS: Statistical het-
erogeneity was found among the 17 PBO responses (mean reduction of UUI) of the
included studies. PBO response increased with publication year, which accounted
for more than 27% of response variation. Publication year (p0.02), gender
(p0.003), and study duration (6-week vs. other) (p0.006) were significant predic-
tors of PBO response (adj. R20.6261). TOL and FESO 8mg treatment effect esti-
mates were also heterogeneous. Among the nine TOL trials, treatment responses
remained constant over publication year while PBO responses increased, resulting
in a net decline in TOL treatment effect (p0.0928). The majority of this decline was
explained by publication year and study duration (adj. R20.7703). The four FESO
8mg UUI responses also displayed a publication year-dependent decrease leading
to a decreasing treatment effect relative to PBO. However, this trend was almost
fully predictable by differential baseline UUI episodes (adj. R20.9721).
CONCLUSIONS: Publication year, gender, 6-week duration, and baseline UUI were
found to be significant predictors of PBO response or treatment effect. Additional
research should be done to understand why PBO response has increased over time
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